Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanespimycin in advanced thyroid carcinoma
NCT00118248Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2004
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tanespimycin in thyroid cancer, follicular thyroid cancer (FTC), papillary thyroid cancer (PTC) and 1 more, sponsored by National Cancer Institute. Primary endpoint: Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin) at 1 year. Started Dec 2004; status: completed.
02
Drugs
tanespimycin
03
Conditions
thyroid cancerfollicular thyroid cancer (FTC)papillary thyroid cancer (PTC)medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT00118248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118248.